How to read hepatitis B guidelines and source links

Guidelines are not your personal diagnosis

Hepatitis B guidelines help explain screening, prevention, monitoring, treatment, and liver cancer surveillance principles, but they are not a personal prescription. Clinicians need to combine guidance with your age, sex, HBV DNA, ALT/AST, HBeAg status, fibrosis or cirrhosis, family history, pregnancy plans, coinfections, immune-suppressing treatment plans, medicine access, and local policy.

When you see a treatment threshold or follow-up interval, turn it into a question: Do I fit the population for this recommendation? Which of my results support or do not support treatment? If I am not treated now, what should be checked next, when, and what change should trigger earlier contact?

Start by identifying the source type

WHO 2024 chronic hepatitis B guidelines have a global public health and implementation focus, including expanded testing, simplified treatment pathways, and treatment access. CDC materials are often useful for screening, serology interpretation, vaccines, exposure response, and US public health settings. AASLD, EASL, and Chinese chronic hepatitis B guidelines are more clinical and discuss indications, stopping, cancer surveillance, special groups, and follow-up in greater detail.

Different sources have different purposes. One source should not be used alone outside your clinical context.

Why guidelines can differ

Guidelines differ because of region, evidence date, public health goals, test and medicine access, cost, insurance, expert consensus, and risk tolerance. Some guidance emphasizes simpler treatment thresholds; some emphasizes more detailed risk stratification. For patients, the useful question is not who is right, but which guideline your clinician uses locally and how your individual risk is being classified.

What to look for first

Check the publication date, target audience, and population. Then look for evidence strength or recommendation strength. Do not quote one number in isolation. Treatment recommendations often consider HBV DNA, ALT, fibrosis, cirrhosis, age, family history, and comorbidities together. Liver cancer surveillance also depends on cirrhosis, age, sex, region, family history, and other risks. Stopping treatment is especially unsafe to copy from the internet because it requires close monitoring.

Use links to improve follow-up visits

Save the guideline sentence or OpenHBV source link, but avoid asking only whether you should follow it. Ask: I saw WHO/EASL/AASLD/Chinese guidance recommending treatment more actively for some groups. Do my results fit? If not, which criteria are missing? If yes, how would medicine choice, follow-up frequency, kidney safety, and bone safety be handled?

Action checklist

Save original reports, not just positive or negative labels. Record guideline name, year, and link. Before the visit, write down HBV DNA, ALT/AST, HBeAg/anti-HBe, platelets, ultrasound or elastography, family history, pregnancy plans, and medicine plans. Ask which local guideline applies to you. If guidelines seem inconsistent, ask the clinician to explain your risk category and next monitoring plan. Do not start, stop, or switch antivirals based on online guidelines.